$4.61
5.49% yesterday
Nasdaq, May 20, 10:11 pm CET
ISIN
US92539P1012
Symbol
VERV

Verve Therapeutics Inc Stock price

$4.61
-0.17 3.56% 1M
+0.06 1.32% 6M
-1.03 18.26% YTD
-1.34 22.52% 1Y
-8.80 65.62% 3Y
-27.31 85.56% 5Y
-27.31 85.56% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.24 5.49%
ISIN
US92539P1012
Symbol
VERV
Sector
Industry

Key metrics

Market capitalization $410.95m
Enterprise Value $-17.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.12
EV/Sales (TTM) EV/Sales -0.29
P/S ratio (TTM) P/S ratio 6.89
P/B ratio (TTM) P/B ratio 0.86
Revenue growth (TTM) Revenue growth 271.44%
Revenue (TTM) Revenue $59.61m
EBIT (operating result TTM) EBIT $-208.45m
Free Cash Flow (TTM) Free Cash Flow $-146.98m
Cash position $497.08m
EPS (TTM) EPS $-2.11
P/E forward negative
P/S forward 8.91
EV/Sales forward negative
Short interest 24.60%
Show more

Is Verve Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Verve Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Verve Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Verve Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Verve Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
60 60
271% 271%
100%
- Direct Costs 6.84 6.84
27% 27%
11%
53 53
690% 690%
89%
- Selling and Administrative Expenses 46 46
39% 39%
77%
- Research and Development Expense 209 209
12% 12%
350%
-202 -202
5% 5%
-338%
- Depreciation and Amortization 6.84 6.84
27% 27%
11%
EBIT (Operating Income) EBIT -208 -208
6% 6%
-350%
Net Profit -181 -181
8% 8%
-304%

In millions USD.

Don't miss a Thing! We will send you all news about Verve Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verve Therapeutics Inc Stock News

Positive
Seeking Alpha
about 18 hours ago
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
Neutral
GlobeNewsWire
7 days ago
Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9
Neutral
GlobeNewsWire
18 days ago
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with...
More Verve Therapeutics Inc News

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Sekar Kathiresan
Employees 274
Founded 2018
Website www.vervetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today